535: A longevity drug exists—would you take it? | Nir Barzilai, M.D., leading longevity researcher

“We have to spend time on our health rather than spend time on diseases," says Nir Barzilai, M.D. Nir, a renowned longevity researcher, joins us to discuss pharmaceutical interventions to delay aging, plus: - What are gerotherapeutics? (~00:19) - What you need to know about antagonistic nutrients (~04:25) - Why healthcare costs don’t have to increase as people live longer (~08:55) - SuperAgers vs. Blue Zones (~12:40) - What are some science-backed longevity genes? (~15:14) - The hallmarks of aging (~19:54) - How metformin extends longevity (~22:46) - Who is the right candidate for longevity drugs? (~25:03) - The best age to take a longevity drug (~31:55) - Lifestyle interventions for healthy aging (~34:17) - Is fasting actually necessary? (~38:18) - What to know about mTOR (~41:19) - How to test your biological age (~43:10) - What to do in your 20s and 30s for healthy aging (~48:16) - The role of mindset in aging (~53:45) - How repurposing drugs has saved lives (~57:45) - Why women have the aging advantage (~01:03:42) Take 25% off vitamin D3 potency+ with code D3POD. Cannot combine with gift cards or other discount codes. Apply code at checkout. Referenced in the episode: - Nir's book, Age Later - Nir's SuperAger study - The SuperAgers family study - Learn about the antagonistic pleiotropy hypothesis of aging - Nir's study on metformin & aging - TAME trial - A study on metformin & COVID outcomes - A study on metformin & muscle hypertrophy - Nir's study on organ aging - A study on metformin & IGF1 - A study on centenarians & IGF1 - Episodes #363, #217 & #170, with David Sinclair, Ph.D. - Episode #207, with David Fajgenbaum, M.D., MBA, M.Sc., FCPP We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: [email protected]. Learn more about your ad choices. Visit megaphone.fm/adchoices